Watson Pharma (WPI) Confirms Patent Challenge on Epiduo Gel

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. FDA seeking approval to market Epiduo® (adapalene and benzoyl peroxide) Gel, 0.1% / 2.5%. Watson's ANDA product is a generic version of Galderma Laboratories, L.P. Epiduo® Gel is a topical ointment prescription drug that combines a retinoid (adapalene) and an antimicrobial (benzoyl peroxide) for the treatment of acne vulgaris (severe acne) in people who are at least 12 years old.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Sky Quarry names Heidi Bowman as CFO
• T3 Defense subsidiary Rimon enters UAV and counter-drone platform market
• Westlake Corp adds dual listing on NYSE Texas exchange